iRhythm Holdings, Inc. (IRTC) company profile
Close on Nov 17, 2026Market cap $2.96BP/E –Yield –
About iRhythm
Surgical & Medical Instruments & Apparatus, SIC 3841
iRhythm is a digital healthcare company providing device-based technology for ambulatory cardiac monitoring. Its offerings combine wearable, patch-based biosensors with cloud-based data analytic software to monitor patients and assist in diagnosing arrhythmias, such as atrial fibrillation. Key systems include the Zio monitor, Zio XT, and Zio AT systems, which support long-term continuous monitoring and mobile cardiac telemetry services. Customers and users primarily comprise physicians, cardiology practices, electrophysiologists, primary care clinicians, integrated delivery networks, and value-based healthcare organizations.
Headquartered in San Francisco, California, the company maintains independent diagnostic testing facilities in the United States and directly markets services domestically. Internationally, the company operates in the United Kingdom, Japan, and several European nations including Switzerland, Austria, the Netherlands, and Spain, utilizing direct sales teams and third-party distribution partners. As of late 2025, the company employed approximately 2,400 regular full-time employees and had processed over twelve million patient reports.
Summary of the business section of iRhythm's latest annual report, written by StockData.
Company profile
Company
- Legal name
- iRhythm Holdings, Inc.
- Founded
- 2006
- Headquarters
- San Francisco, CA
- Address
- 699 8th Street, Suite 600 94103
- Phone
- (415) 632-5700
- Website
- irhythmtech.com
- Employees
- 2,400, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- IRTC
- Exchange
- Nasdaq
- IPO date
- Oct 20, 2016
- Shares outstanding
- 33M, Jul 30, 2026
- Public float
- $4.90B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1388658
- CUSIP
- 450056106
- ISIN
- US4500561067
- FIGI
- BBG001J19V24
- Share class FIGI
- BBG001TSQV70
- LEI
- 549300FJI72RJGDQS384
- EIN
- 41-3421287
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Quentin S. Blackford | President and CEO, Director | 226,008 |
| Daniel G. Wilson | Chief Financial Officer | 34,987 |
| Sumi Shrishrimal | EVP, Chief Risk Officer | 44,621 |
| Minang Turakhia | CHIEF MED/SCI OFCR EVP ADVTECH | 60,116 |
| Chad Patterson | CHIEF COMM & PRODUCT OFFICER | 62,125 |
| Patrick Michael Murphy | CBO and CLO | 69,699 |
| Mervin Smith | EVP Strategic Business Ops | 22,410 |
| Julianne Rodda | EVP, CHIEF PEOPLE OFFICER | 18,201 |
| Sean Clinton Freeman | EVP, Strategy & Corp Devt | 13,641 |
| Marc Wade Rosenbaum | Chief Accounting Officer | 16,155 |
| Brian Lee Lawrence | Chief Technology Officer | 20,154 |
| Karen K. McGinnis | Director | 3,608 |
| Abhijit Y. Talwalkar | Director | 21,872 |
| Brian B. Yoor | Director | 7,171 |
| Bruce G. Bodaken | Director | 14,211 |
| Merz Cathleen Noel Bairey | Director | 10,546 |
| Karen Ling | Director | 11,141 |
| Kevin C. Oboyle | Director | 3,608 |
| Jason H. Patten | Director | 4,436 |
| Ralph Snyderman | Director | 13,288 |
| Mark J. Rubash | Director | 13,788 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $11.00M | $45.12M | $3.45M | $75 | $79 |
| FY2024 | $9.34M | $1.29M | $3.05M | $38 | $79 |
| FY2023 | $16.60M | $16.26M | $5.42M | $45 | $75 |
| FY2022 | $7.97M | $5.27M | $4.42M | $39 | $79 |
| FY2021 Douglas Devine | $5.70M | $2.90M | $3.36M | $50 | $104 |
| FY2021 Kevin King | $30.71K | -$9.81M | $3.36M | $50 | $104 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Quentin Blackford President and Chief Executive Officer | $700.00K | $8.92M | $1.35M | $33.70K | $11.00M | +18% |
| Daniel Wilson Chief Financial Officer | $446.16K | $2.07M | $490.50K | $33.54K | $3.04M | +20% |
| Patrick Murphy Chief Business Officer and Chief Legal Officer | $468.65K | $2.07M | $486.50K | $32.20K | $3.06M | +2% |
| Chad Patterson Chief Commercial Officer | $495.96K | $2.80M | $750.00K | $33.45K | $4.08M | +12% |
| Minang (Mintu) Turakhia, M.D., M.S. Chief Medical and Scientific Officer, and EVP, Advanced Technologies | $478.59K | $2.59M | $523.20K | $31.30K | $3.63M | +9% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 20, 2016
- Offer price
- $17.00
- Securities offered
- 6,294,118
- Gross proceeds
- $107.00M
- Exchange
- Nasdaq
- First trading day
- Oct 20, 2016
- First-day close
- $26.05+53.2%
- Lock-up ends (est.)
- Apr 18, 2017
“Per Share Total Initial Public Offering Price $ 17.00 $ 107,000,006 Underwriting Discounts and Commissions (1) $ 1.19 $ 7,490,000 Proceeds to iRhythm Technologies, Inc.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 2,400 employees globally.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 1, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jan 30, 2026 | Deregistration | Termination of SEC registration (Form 15) |
| Jan 12, 2026 | Name change | Name changed from iRhythm Technologies, Inc. to iRhythm Holdings, Inc. |
| Nov 19, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 13, 2019 | Late filing | Notification of late filing |
| Jul 31, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 4, 2019 | Late filing | Notification of late filing |
| Oct 20, 2016 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 13, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?